mitoxantrone has been researched along with Agranulocytosis in 21 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Agranulocytosis: A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 9.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "The toxicity of escalating doses of liposome-complexed mitoxantrone (LCM) was evaluated in 22 women with histological/cytological diagnosis of metastatic breast cancer (21 pts) or adenocarcinoma of unknown primary origin (1 pt)." | 7.68 | Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. ( Pestalozzi, B; Sauter, C; Schwendener, R, 1992) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 6.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 5.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| " A phase II study was performed at the MTD of paclitaxel in patients with doxorubicin/mitoxantrone-refractory metastatic breast cancer." | 5.07 | Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. ( Bates, S; Berg, SL; Bryant, G; Fojo, A; Goldspiel, BR; Herdt, J; O'Shaughnessy, J; Steinberg, SM; Wilson, WH; Wittes, RE, 1994) |
| "The toxicity of escalating doses of liposome-complexed mitoxantrone (LCM) was evaluated in 22 women with histological/cytological diagnosis of metastatic breast cancer (21 pts) or adenocarcinoma of unknown primary origin (1 pt)." | 3.68 | Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. ( Pestalozzi, B; Sauter, C; Schwendener, R, 1992) |
| "Mitoxantrone was administered as a single iv injection once every 3 weeks to 84 children with advanced acute leukemia and solid tumors in a phase I trial." | 3.67 | Phase I trial of mitoxantrone in children. ( Cohen, LF; Glaubiger, DL; Holcenberg, JS; Kamen, BA; Pratt, CB; Ungerleider, RS; Vietti, TJ, 1985) |
| "In patients with advanced-stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades." | 2.72 | Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly ( Dreyling, M; Hiddemann, W; Hoster, E; Lengfelder, E; Nickenig, C; Pfreundschuh, M; Reiser, M; Trumper, L; Unterhalt, M; Wandt, H, 2006) |
| " every 3 weeks in escalating doses combined with a fixed dose of s." | 2.67 | Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors. ( Dal Fior, S; Favretto, S; Gasparini, G; Panizzoni, GA; Pozza, F; Von Hoff, DD, 1991) |
| "Mitoxantrone was administered intravenously at a dose of 14 mg/m2 every 3 weeks." | 2.66 | Phase II trial of mitoxantrone in advanced gastric cancer. ( Benedetto, P; Goldenberg, A; Kelsen, D, 1988) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 2.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Acute airway obstruction caused by mucoid impaction can cause sometimes life-threatening respiratory distress." | 1.33 | [Acute airway obstruction during chemotherapy-induced agranulocytosis with fever]. ( Bernardin, G; Burel-Vandenbos, F; Deswardt, P; Hyvernat, H; Vandenbos, F, 2006) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 1.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks." | 1.26 | Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 8 (38.10) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, LY | 1 |
| Li, QH | 1 |
| Huang, ZL | 1 |
| Lin, W | 1 |
| Lu, ZS | 1 |
| Weng, JY | 1 |
| Wu, SJ | 1 |
| Du, X | 1 |
| Vandenbos, F | 1 |
| Deswardt, P | 1 |
| Hyvernat, H | 1 |
| Burel-Vandenbos, F | 1 |
| Bernardin, G | 1 |
| Nickenig, C | 1 |
| Dreyling, M | 1 |
| Hoster, E | 1 |
| Pfreundschuh, M | 1 |
| Trumper, L | 1 |
| Reiser, M | 1 |
| Wandt, H | 1 |
| Lengfelder, E | 1 |
| Unterhalt, M | 1 |
| Hiddemann, W | 2 |
| Lü, SQ | 1 |
| Yang, JM | 1 |
| Song, XM | 1 |
| Chen, L | 1 |
| Zhang, WP | 1 |
| Ni, X | 1 |
| Xu, XQ | 1 |
| Wang, JM | 1 |
| Stuart-Harris, RC | 1 |
| Bozek, T | 1 |
| Pavlidis, NA | 1 |
| Smith, IE | 1 |
| Presant, CA | 1 |
| Gams, R | 3 |
| Bartolucci, AA | 1 |
| Anderson, KC | 1 |
| Cohen, GI | 1 |
| Garnick, MB | 1 |
| Yap, HY | 1 |
| Blumenschein, GR | 1 |
| Schell, FC | 1 |
| Buzdar, AU | 1 |
| Valdivieso, M | 1 |
| Bodey, GP | 1 |
| Avilés, A | 1 |
| Guzmán, R | 1 |
| Talavera, A | 1 |
| García, EL | 1 |
| Díaz-Maqueo, JC | 1 |
| McLaughlin, P | 1 |
| Hagemeister, FB | 1 |
| Swan, F | 1 |
| Cabanillas, F | 1 |
| Romaguera, J | 1 |
| Rodriguez, MA | 1 |
| Lee, MS | 1 |
| Pate, O | 1 |
| Sarris, A | 1 |
| Younes, A | 1 |
| Wilson, WH | 1 |
| Berg, SL | 1 |
| Bryant, G | 1 |
| Wittes, RE | 1 |
| Bates, S | 1 |
| Fojo, A | 1 |
| Steinberg, SM | 1 |
| Goldspiel, BR | 1 |
| Herdt, J | 1 |
| O'Shaughnessy, J | 1 |
| Tobita, T | 1 |
| Shinjyo, K | 1 |
| Yanagi, M | 1 |
| Takeshita, A | 1 |
| Ohnishi, K | 1 |
| Ohno, R | 1 |
| Mariańska, B | 1 |
| Apel, D | 1 |
| Seferyńska, I | 1 |
| Maj, S | 1 |
| Pestalozzi, B | 1 |
| Schwendener, R | 1 |
| Sauter, C | 1 |
| Gasparini, G | 1 |
| Dal Fior, S | 1 |
| Pozza, F | 1 |
| Panizzoni, GA | 1 |
| Favretto, S | 1 |
| Von Hoff, DD | 1 |
| Essink, ME | 1 |
| von Eiff, M | 1 |
| Büchner, T | 1 |
| van de Loo, J | 1 |
| Goldenberg, A | 1 |
| Kelsen, D | 1 |
| Benedetto, P | 1 |
| DeSimone, PA | 2 |
| Bartolucci, A | 1 |
| Birch, R | 1 |
| Ungerleider, RS | 1 |
| Pratt, CB | 1 |
| Vietti, TJ | 1 |
| Holcenberg, JS | 1 |
| Kamen, BA | 1 |
| Glaubiger, DL | 1 |
| Cohen, LF | 1 |
| Prentice, HG | 1 |
| Wimperis, JZ | 1 |
| Robbins, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Exploring Patient Engagement Patterns and Participation Trends in Mantle Cell Lymphoma Clinical Trials[NCT06049472] | 500 participants (Anticipated) | Observational | 2024-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 trials available for mitoxantrone and Agranulocytosis
| Article | Year |
|---|---|
Regimen containing perarubicin for the treatment of newly diagnosed young patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Agranulocytosis; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cytara | 2009 |
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell ly
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclopho | 2006 |
Randomized study for the treatment of adult advanced Hodgkin's disease: epirubicin, vinblastine, bleomycin, and dacarbazine (EVBD) versus mitoxantrone, vinblastine, bleomycin, and dacarbazine (MVBD).
Topics: Actuarial Analysis; Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protoco | 1994 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomark | 1994 |
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Topics: Adult; Aged; Agranulocytosis; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Resi | 1994 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Femal | 1998 |
Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation | 1991 |
Phase II trial of mitoxantrone in advanced gastric cancer.
Topics: Adult; Aged; Agranulocytosis; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middl | 1988 |
Weekly mitoxantrone in the treatment of advanced pancreatic carcinoma: a Southeastern Cancer Study Group Trial.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Clinical Trials as Topic; Femal | 1986 |
Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Clinical Trials | 1986 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone | 1985 |
10 other studies available for mitoxantrone and Agranulocytosis
| Article | Year |
|---|---|
[Acute airway obstruction during chemotherapy-induced agranulocytosis with fever].
Topics: Agranulocytosis; Airway Obstruction; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Cyt | 2006 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa | 2007 |
Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female | 1984 |
Treatment of metastatic sarcomas with mitoxantrone.
Topics: Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Drug Evaluation; Female; Hum | 1984 |
Phase II trial of mitoxantrone.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Heart; | 1982 |
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthracenes; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Dru | 1981 |
Relapse in the external auditory canal of acute promyelocytic leukemia after treatment with all-trans retinoic acid.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modalit | 1997 |
Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer.
Topics: Adenocarcinoma; Agranulocytosis; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Carriers; | 1992 |
Effect of antifungal therapy on hematological recovery after intensive antileukemic chemotherapy.
Topics: Agranulocytosis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1990 |
Phase I trial of mitoxantrone in children.
Topics: Acute Disease; Adolescent; Agranulocytosis; Anthraquinones; Child; Child, Preschool; Dose-Response R | 1985 |